AMPEL BioSolutions

AMPEL BioSolutions is a precision medicine company that uses computational biology, RNA analytics, and predictive AI to develop diagnostic and disease management tools for autoimmune and inflammatory diseases. Founded in 2014, the company's core offering is the AMPEL Genomic Platform (AGP®), which analyzes genomic data to create a patient's 'Genomic Fingerprint' for personalized care. Its first commercial product, LuGENE®, is a blood test for lupus that predicts disease flares and identifies potential drug targets.